Olema Pharmaceuticals: Growing hope for new options for resistant tumors

Olema Pharmaceuticals is focusing on novel therapies against hormone-dependent breast cancer, working on compounds that specifically interfere with the estrogen receptor signaling pathway. At the center is a candidate aimed at slowing down tumor cells even when conventional treatments lose their effectiveness. The company is positioning itself in a field where the medical need is great and new mechanisms are receiving particular attention. Early study data suggesting a stable efficacy profile is increasing investor interest, as Olema is seen as...